StephenPatrickAnthonyDO

PubMed

• 4 citations
  CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
  Charles Peterfy, Yan Chen, Peter Countryman, Bartosz Chmielowski, Stephen P Anthony, John H Healey, Zev A Wainberg, Allen L Cohn, Geoffrey I Shapiro, Vicki L Keedy, Ar...> ;Future Oncology. 2022 Apr 1
• 3 citations
  A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
  Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen W.L. Yee, Andrew Dalovisio, Eunice S. Wang, Jua...> ;Blood Cancer Journal. 2021 Oct 30
• 7 citations
  Results from Phase 1 Extension Study Assessing Pexidartinib Treatment in 6 cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
  William D. Tap, Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Z...> ;Clinical Cancer Research. 2021 Oct 29
• 5 citations
  Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.
  Mariaelena Pierobon, Nicholas J. Robert, Donald W. Northfelt, Mohammad Jahanzeb, Shukmei Wong, Kimberly A. Hodge, Elisa Baldelli, Jessica Aldrich, David Craig, Lance A...> ;Molecular Oncology. 2021 Sep 12
• 13 citations
  Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
  Joshua F. Zeidner, Daniel J. Lee, Mark G. Frattini, Gil Fine, Judy Costas, Kathryn Kolibaba, Stephen P. Anthony, David J. Bearss, B. Douglas Smith> ;Clinical Cancer Research. 2021 Jan 1
• 6 citations
  Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
  Jennifer Brown, Ruth Plummer, Todd M. Bauer, Stephen Anthony, John Sarantopoulos, Filip de Vos, Mike White, Marco Schupp, Ying Ou, Ulka N. Vaishampayan> ;Experimental Hematology & Oncology. 2017 Oct 3
• 64 citations
  Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
  Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich, Sara A. Byron, Stephen P. Anthony, Nicholas J. Robert, Donald W. Northfelt, Mohammad ...> ;Clinical Cancer Research. 2017 Aug 15
• 3 citations
  Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation
  Eric Cheung, William Jeffery Edenfield, Bassam Mattar, Stephen P. Anthony, Peter J. Mutch, Brian Chanas, Mark S. Smith, Adrian Hepner> ;Journal of Clinical Pharmacology. 2017 May 31
• 75 citations
  Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
  , , , , , , , , , , , , , , , , , , , > ;Clinical Therapeutics. 2016 Apr 1
• 346 citations
  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
  William D. Tap, Zev A. Wainberg, Stephen P. Anthony, Prabha N. Ibrahim, Chao Zhang, John H. Healey, Bartosz Chmielowski, Arthur P Staddon, Allen Lee Cohn, Geoffrey I. ...> ;The New England Journal of Medicine. 2015 Jul 29
• 4 citations
  A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and...
  Mitesh J. Borad, Hani M. Babiker, Stephen P. Anthony, Monica M. Mita, Aby Buchbinder, Taha Keilani, Jean L. Grem> ;Cancer Investigation. 2015 May 20
• 37 citations
  Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
  Pilar Ramos, Anthony N. Karnezis, William P.D. Hendricks, Yemin Wang, Waibhav Tembe, Victoria Zismann, Christophe Legendre, Winnie S. Liang, Megan Russell, David Craig...> ;Rare Diseases. 2014 Nov 3
• 59 citations
  A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic b...
  Gayle S. Jameson, Emanuel F. Petricoin, Jasgit C. Sachdev, Lance A. Liotta, David M. Loesch, Stephen P. Anthony, Manpreet K. Chadha, Julia Wulfkuhle, Rosa I. Gallagher...> ;Breast Cancer Research and Treatment. 2014 Sep 11
• 245 citations
  Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
  Pilar Ramos, Anthony N. Karnezis, David Craig, Aleksandar Sekulic, Megan Russell, William P.D. Hendricks, Jason J. Corneveaux, Michael T. Barrett, Karey Shumansky, Yid...> ;Nature Genetics. 2014 May 1
• 23 citations
  A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
  Michael S. Gordon, Lee S. Rosen, David S. Mendelson, Ramesh K. Ramanathan, Jonathan W. Goldman, Lili Liu, Yan Xu, Stanton L. Gerson, Stephen P. Anthony, William D. Fig...> ;Investigational New Drugs. 2013 Jun 1
• 44 citations
  Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every...
  Glen J. Weiss, Ross C. Donehower, Tara Iyengar, Ramesh K. Ramanathan, Karen Lewandowski, Eric H. Westin, Karla Hurt, Scott M. Hynes, Stephen P. Anthony, Scott McKane> ;Investigational New Drugs. 2013 Feb 1
• 40 citations
  A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
  Gayle S. Jameson, John T. Hamm, Glen J. Weiss, Carlos Alemany, Stephen P. Anthony, Michele Basche, Ramesh K. Ramanathan, Mitesh J. Borad, Raoul Tibes, Allen Lee Cohn, ...> ;Clinical Cancer Research. 2013 Jan 1
• 100 citations
  Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
  Daruka Mahadevan, E. G. Chiorean, Wayne Harris, D. D. Von Hoff, A. Stejskal-Barnett, Wenqing Qi, Stephen P. Anthony, A. E. Younger, D. M. Rensvold, F. Cordova, C. F. S...> ;European Journal of Cancer. 2012 Dec 1
• 11 citations
  Molecular Characterization of a Patient's Small Cell Carcinoma of the Ovary of the Hypercalcemic Type.
  Bret Stephens, Stephen P. Anthony, Haiyong Han, Jeffery Kiefer, Galen Hostetter, Michael T. Barrett, Daniel D. Von Hoff> ;Journal of Cancer. 2012 Jan 1
• Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.
  Anthony SP, Puzanov I, Lin PS, Nolop KB, West B, Von Hoff DD> ;J. Clin. Oncol.. 2011-05-20
• 461 citations
  Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
  Daniel D. Von Hoff, J. Stephenson, Peter Rosen, David M. Loesch, Mitesh J. Borad, Stephen P. Anthony, Gayle S. Jameson, Susan Brown, Nina Cantafio, Donald A. Richards,...> ;Journal of Clinical Oncology. 2010 Nov 20
• 63 citations
  Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
  Robert M Eager, Casey Cunningham, Neil Senzer, Joe Stephenson, Stephen P. Anthony, Steven J. O'Day, G. Frenette, Anna C. Pavlick, Barry Jones, Margaret J. Uprichard, J...> ;BMC Cancer. 2009 Jul 30
• A phase I study of daily oral TRC102 (methoxyamine) to enhance the therapeutic effects of pemetrexed in patients with advanced refractory cancer.
  Anthony SP, Rosen LS, Weiss GJ, Gordon MS, Adams BJ, Gerson SL, Alvarez D, Theuer CP, Leigh BR> ;J. Clin. Oncol.. 2009-05-20
• A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors.
  Sausville E, Garbo L, Weiss GJ, Anthony S, Shkolny D, Yurkovetskiy AV, Bethune C, Fram RJ> ;J. Clin. Oncol.. 2009-05-20
• Prospective evaluation of patient perceptions and willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.
  Smith J, Benjamin M, Yim JH, James RL, Ramanathan RK, Anthony SP, Borad M, Bay RC, Piper BF, Tibes R> ;J. Clin. Oncol.. 2009-05-20
• Join now to see all

Lectures

• Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018